Page last updated: 2024-12-05

cinnamamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

cinnamamide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cinnamamide : The simplest member of the class of cinnamamides that consists of acrylamide bearing a phenyl substituent at the 3-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

trans-cinnamamide : The E (trans) isomer of cinnamamide. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5273472
CHEBI ID23246
CHEBI ID76320
MeSH IDM0366538

Synonyms (71)

Synonym
BB 0254398
2-benzylideneacetamide
cinnamamide
3-phenylacrylamide
cinnamic amide
wln: zv1u1r
621-79-4
3-phenylpropenamide
nsc-32953
nsc32953
2-propenamide, 3-phenyl-
nsc244944
22031-64-7
trans-cinnamamide
trans-cinnamoylamine
cinnamamide, (e)-
trans cinnamic acid amide
trans-.beta.-(aminocarbonyl)styrene
nsc-244944
3-phenyl-2-propenamide
ginnamic acid amide
nsc 32953
einecs 210-707-8
ai3-03764
brn 2040577
3-phenyl-acrylamide
(e)-3-phenylprop-2-enamide
cinnamamide, predominantly trans, 97%
trans-3-phenylacrylamide
3-phenylprop-2-enamide
AKOS005071667
A833630
(e)-3-phenylprop-2-enamide;cinnamamide (predominantly trans)
(e)-3-phenyl-acrylamide
nsc 244944
2-propenamide, 3-phenyl-, (2e)-
unii-y0jet56h7n
trans-beta-(aminocarbonyl)styrene
2-propenamide, 3-phenyl-, (e)-
y0jet56h7n ,
AS-0058
(2e)-3-phenylprop-2-enamide
cinnamamide (predominantly trans)
trans-cinnamic acid amide
CHEBI:23246
CHEBI:76320
(e)-3-phenylacrylamide
cinnamide
cinnanamide
u-2422
(e)-cinnamamide
3-phenyl-2-propenoic amide, (e)-
mitomycin impurity a [ep impurity]
coumaramide
DTXSID4060739
dh6 ,
(2e)-3-phenyl-2-propenamide #
W-105038
J-520049
mfcd00008033
J-014435
CS-W018211
cinnamamide, predominantly trans
Q63390539
zimtsa currencyureamid
AC7815
(2e)-3-phenyl-2-propenamide
(e)-3-phenylprop-2-enamide (trans-cinnamamide)
cinnamamide(predominantlytrans)
DTXSID901035045
HY-W017495

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Hence in order to enhance the dosage in mitochondrial fraction of cinnamamides, the mitochondria-targeted derivatives were designed by the incorporation of cinnamamides into a fluorophore carrier of coumarin-3-carboxamide with a 1:1 stoichiometry."( Synthesis, mitochondrial localization of fluorescent derivatives of cinnamamide as anticancer agents.
He, D; Li, Y; Tang, Q; Yang, K; Zheng, L, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cinnamamideThe simplest member of the class of cinnamamides that consists of acrylamide bearing a phenyl substituent at the 3-position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (54)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.85)18.7374
1990's0 (0.00)18.2507
2000's10 (18.52)29.6817
2010's34 (62.96)24.3611
2020's9 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.64%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other53 (96.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]